StockData
Biogen Inc. logo

Biogen Inc. (BIIB) stock

BIIBNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 28, 2026Score 4/3056% above fair value
$250.79−0.86 (-0.34%)

Close on Nov 17, 2026Market cap $37.07BP/E 107.2Yield –

Biogen ebitda

EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.

Biogen's ebitda for the twelve months ending Mar 31, 2022 was $3.01B, down 27.5% year over year. For fiscal 2021 it was $3.33B, down 33.5% from the year before. Over ten years it grew 4.8% a year on average. The highest annual figure on record is $7.51B in fiscal 2019.

Annual ebitda

PeriodPeriod endValueChange
FY2021Dec 31, 2021$3.33B-33.5%
FY2020Dec 31, 2020$5.01B-33.3%
FY2019Dec 31, 2019$7.51B+14.8%
FY2018Dec 31, 2018$6.54B+1.7%
FY2017Dec 31, 2017$6.43B+10.2%
FY2016Dec 31, 2016$5.83B+6.2%
FY2015Dec 31, 2015$5.49B+17.8%
FY2014Dec 31, 2014$4.66B+52.9%
FY2013Dec 31, 2013$3.05B+37.2%
FY2012Dec 31, 2012$2.22B+6.6%
FY2011Dec 31, 2011$2.08B+29.9%
FY2010Dec 31, 2010$1.60B-6.9%
FY2009Dec 31, 2009$1.72B+2.8%
FY2008Dec 31, 2008$1.68B+44.4%
FY2007Dec 31, 2007$1.16B–

Quarterly ebitda

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q1 FY2022Mar 31, 2022$753.80M-30.0%
Q4 FY2021Dec 31, 2021$721.80M–
Q3 FY2021Sep 30, 2021$927.20M-22.8%
Q2 FY2021Jun 30, 2021$602.90M-71.1%
Q1 FY2021Mar 31, 2021$1.08B-44.5%
Q4 FY2020Dec 31, 2020-$220.90M-113.2%
Q3 FY2020Sep 30, 2020$1.20B-43.8%
Q2 FY2020Jun 30, 2020$2.09B+0.7%
Q1 FY2020Mar 31, 2020$1.94B+19.5%
Q4 FY2019Dec 31, 2019$1.67B+19.1%
Q3 FY2019Sep 30, 2019$2.14B+4.5%
Q2 FY2019Jun 30, 2019$2.07B+49.7%
Q1 FY2019Mar 31, 2019$1.62B-4.7%
Q4 FY2018Dec 31, 2018$1.41B-16.0%
Q3 FY2018Sep 30, 2018$2.04B+11.6%
Q2 FY2018Jun 30, 2018$1.38B+0.1%
Q1 FY2018Mar 31, 2018$1.70B+10.9%
Q4 FY2017Dec 31, 2017$1.68B+57.3%
Q3 FY2017Sep 30, 2017$1.83B–
Q2 FY2017Jun 30, 2017$1.38B–
Q1 FY2017Mar 31, 2017$1.54B–
Q4 FY2016Dec 31, 2016$1.06B–

More Biogen figures

See a number that looks wrong?